NYSEAMERICAN:OCX - OncoCyte Stock Price, News & Analysis

$1.86
-0.05 (-2.62 %)
(As of 08/25/2019 09:23 AM ET)
Today's Range
$1.76
Now: $1.86
$1.91
50-Day Range N/A
52-Week Range
$1.16
Now: $1.86
$6.92
Volume146,876 shs
Average Volume688,548 shs
Market Capitalization$96.67 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:OCX
CUSIPN/A
Phone(510) 775-0515

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees12
Market Cap$96.67 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive OCX News and Ratings via Email

Sign-up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter.


OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions

What is OncoCyte's stock symbol?

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

How were OncoCyte's earnings last quarter?

OncoCyte Corp (NYSEAMERICAN:OCX) released its quarterly earnings data on Wednesday, August, 14th. The biotechnology company reported ($0.10) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.10). View OncoCyte's Earnings History.

When is OncoCyte's next earnings date?

OncoCyte is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for OncoCyte.

What price target have analysts set for OCX?

5 brokers have issued 1 year price objectives for OncoCyte's stock. Their forecasts range from $6.00 to $8.00. On average, they expect OncoCyte's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 276.3% from the stock's current price. View Analyst Price Targets for OncoCyte.

What is the consensus analysts' recommendation for OncoCyte?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OncoCyte.

Has OncoCyte been receiving favorable news coverage?

News coverage about OCX stock has been trending positive on Sunday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. OncoCyte earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the next several days. View News Stories for OncoCyte.

Are investors shorting OncoCyte?

OncoCyte saw a decrease in short interest in the month of July. As of July 31st, there was short interest totalling 1,007,700 shares, a decrease of 18.8% from the June 30th total of 1,240,400 shares. Based on an average trading volume of 365,900 shares, the days-to-cover ratio is presently 2.8 days. Currently, 3.3% of the company's shares are short sold. View OncoCyte's Current Options Chain.

Who are some of OncoCyte's key competitors?

What other stocks do shareholders of OncoCyte own?

Who are OncoCyte's key executives?

OncoCyte's management team includes the folowing people:
  • Mr. William Annett, Pres, CEO & Director (Age 65)
  • Mr. Mitchell S. Levine, Chief Financial Officer
  • Dr. Lyndal K. Hesterberg, Chief Scientific Officer
  • Mr. Albert P. Parker II, Chief Operating Officer
  • Dr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 66)

Who are OncoCyte's major shareholders?

OncoCyte's stock is owned by many different of institutional and retail investors. Top institutional investors include Emerald Mutual Fund Advisers Trust (4.58%), BlackRock Inc. (2.99%), Vanguard Group Inc. (2.72%), Maven Securities LTD (0.41%), Bank of New York Mellon Corp (0.15%) and Northern Trust Corp (0.14%). Company insiders that own OncoCyte stock include Biotime Inc and Broadwood Partners, LP. View Institutional Ownership Trends for OncoCyte.

Which major investors are selling OncoCyte stock?

OCX stock was sold by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust and Morgan Stanley. View Insider Buying and Selling for OncoCyte.

Which major investors are buying OncoCyte stock?

OCX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Maven Securities LTD, Vanguard Group Inc., Jane Street Group LLC, Bank of New York Mellon Corp, Doheny Asset Management CA, Charles Schwab Investment Management Inc. and Wells Fargo & Company MN. View Insider Buying and Selling for OncoCyte.

How do I buy shares of OncoCyte?

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $1.86.

How big of a company is OncoCyte?

OncoCyte has a market capitalization of $96.67 million. OncoCyte employs 12 workers across the globe.View Additional Information About OncoCyte.

What is OncoCyte's official website?

The official website for OncoCyte is http://www.oncocyte.com/.

How can I contact OncoCyte?

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515.


MarketBeat Community Rating for OncoCyte (NYSEAMERICAN OCX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  140 (Vote Outperform)
Underperform Votes:  117 (Vote Underperform)
Total Votes:  257
MarketBeat's community ratings are surveys of what our community members think about OncoCyte and other stocks. Vote "Outperform" if you believe OCX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel